Keming Gao1, Jodi G Arnold1, Thomas J Prihoda1, Marlon Quinones1, Vivek Singh1, Martha Schinagle1, Carla Conroy1, Nicole D'Arcangelo1, Yuanhan Bai1, Joseph R Calabrese1, Charles L Bowden1. 1. Gao, MD, PhD, Schinagle, MD, Calabrese, MD, Mood and Anxiety Clinic in the Mood Disorders Program, Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, Ohio, and Case Western Reserve University School of Medicine, Cleveland, Ohio. Arnold, PhD, Bowden, MD, Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas. Prihoda, PhD, Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. Quinones, MD, IKARE Mood, Trauma, and Recovery Clinic, San Antonio, Texas. Singh, MD, Department of Psychiatry, Texas Tech University Health Sciences Center at El Paso, El Paso, Texas. Conroy, MPH, D'Arcangelo, MSW, Case Western Reserve University School of Medicine. Cleveland, Ohio. Bai, MD, MS, Mood and Anxiety Clinic in the Mood Disorders Program, Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, Ohio, and Shenzhen Kangning Hospital, Shenzhen, Guandong Province, China.
Abstract
Objectives: To sequentially study the effectiveness of lithium and divalproex monotherapy and adjunctive therapy with quetiapine or lamotrigine in the acute and continuation treatment of bipolar I or II disorder at any phase of illness and at least mild symptom severity. Methods: From June 2011 to December 2016, patients with bipolar I or II disorder (using DSM-IV diagnostic criteria) and CGI-S (Clinical Global Impression-Severity) ⩾ 3 were randomized to receive lithium or divalproex monotherapy for 2 weeks. Patients who had CGI-S-depression ⩾ 3 for 2 weeks at any time after 2-week monotherapy were randomly assigned to receive quetiapine or lamotrigine, or remaining on monotherapy for a total of 26 weeks. Results: The rates of early termination due to lack of efficacy and side effects and changes in BISS (Bipolar Inventory of Symptoms Scale) and CGI-S total score were not significantly different between lithium and divalproex. The completion rate was significantly higher with adjunctive therapy than with monotherapy. BISS and CGI-S total scores, and their sub-scores were significantly reduced with adjunctive therapy compared to monotherapy. Adjunctive therapy significantly increased survival times compared to monotherapy (hazard ratio = 6.8), and the monotherapy group had a significantly increased risk for not reaching sustained recovery from depression (hazard ratio = 12.7). Patients who did not need the 2nd randomization and remained on monotherapy had a significantly reduced hazard for discontinuation (hazard ratio = 3.8). Conclusions: The efficacy of lithium and divalproex as monotherapy was modest. Adjunctive lamotrigine and quetiapine to either one was well-tolerated and equally effective in reducing bipolar symptomatology, but adjunctive therapy should be initiated as early as possible when depression symptoms are present.
Objectives: To sequentially study the effectiveness of lithium and divalproex monotherapy and adjunctive therapy with quetiapine or lamotrigine in the acute and continuation treatment of bipolar I or II disorder at any phase of illness and at least mild symptom severity. Methods: From June 2011 to December 2016, patients with bipolar I or II disorder (using DSM-IV diagnostic criteria) and CGI-S (Clinical Global Impression-Severity) ⩾ 3 were randomized to receive lithium or divalproex monotherapy for 2 weeks. Patients who had CGI-S-depression ⩾ 3 for 2 weeks at any time after 2-week monotherapy were randomly assigned to receive quetiapine or lamotrigine, or remaining on monotherapy for a total of 26 weeks. Results: The rates of early termination due to lack of efficacy and side effects and changes in BISS (Bipolar Inventory of Symptoms Scale) and CGI-S total score were not significantly different between lithium and divalproex. The completion rate was significantly higher with adjunctive therapy than with monotherapy. BISS and CGI-S total scores, and their sub-scores were significantly reduced with adjunctive therapy compared to monotherapy. Adjunctive therapy significantly increased survival times compared to monotherapy (hazard ratio = 6.8), and the monotherapy group had a significantly increased risk for not reaching sustained recovery from depression (hazard ratio = 12.7). Patients who did not need the 2nd randomization and remained on monotherapy had a significantly reduced hazard for discontinuation (hazard ratio = 3.8). Conclusions: The efficacy of lithium and divalproex as monotherapy was modest. Adjunctive lamotrigine and quetiapine to either one was well-tolerated and equally effective in reducing bipolar symptomatology, but adjunctive therapy should be initiated as early as possible when depression symptoms are present.
Authors: Benedikt Amann; Christoph Born; Jose Manuel Crespo; Edith Pomarol-Clotet; Peter McKenna Journal: J Psychopharmacol Date: 2010-09-07 Impact factor: 4.153
Authors: Mark Zimmerman; Carolina Guzman Holst; Heather L Clark; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian Journal: CNS Drugs Date: 2016-12 Impact factor: 5.749
Authors: David E Kemp; Keming Gao; Elizabeth B Fein; Philip K Chan; Carla Conroy; Sarah Obral; Stephen J Ganocy; Joseph R Calabrese Journal: Bipolar Disord Date: 2012-11 Impact factor: 6.744
Authors: Lakshmi N Yatham; Eduard Vieta; Allan H Young; Hans-Jürgen Möller; Björn Paulsson; Mårten Vågerö Journal: Int Clin Psychopharmacol Date: 2007-07 Impact factor: 1.659
Authors: David E Kemp; Keming Gao; Stephen J Ganocy; Omar Elhaj; Sarah R Bilali; Carla Conroy; Robert L Findling; Joseph R Calabrese Journal: J Clin Psychiatry Date: 2008-12-30 Impact factor: 4.384
Authors: Michel S Bourin; Emanuel Severus; Juan P Schronen; Peter Gass; Johan Szamosi; Hans Eriksson; Hongally Chandrashekar Journal: Int J Bipolar Disord Date: 2014-11-08